Recombinant Mouse IDO Protein (N-6His)

Beta LifeScience SKU/CAT #: BL-1632NP
BL-1632NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-1632NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Mouse IDO Protein (N-6His)

Beta LifeScience SKU/CAT #: BL-1632NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Mouse Indoleamine 2,3-dioxygenase is produced by our E.coli expression system and the target gene encoding Met1-Pro407 is expressed with a 6His tag at the N-terminus.
Accession P28776
Synonym Indole 2;3-dioxygenase; Indoleamine 2;3-dioxygenase 1; IDO-1; IDO1; IDO; INDO
Gene Background Indoleamine 2,3-dioxygenase (IDO) is a heme enzyme that initiates the oxidative degradation of the least abundant, essential amino acid, l-tryptophan, along the kynurenine pathway. This protein is normally expressed in the dendritic cells, macrophages, microglia, eosinophils, fibroblasts, endothelial cells, and most tumor cells. IDO activity is associated with immunosuppression and immune attenuation. Several studies showed that IDO can contribute to immune escape when expressed directly in tumor cells or when expressed in immunosuppressive antigen presenting cells such as tolerogenic dendritic cells or tumor associated macrophages. IDO also is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression.
Molecular Mass 47.1 KDa
Apmol Mass 40-50 KDa, reducing conditions
Formulation Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 500mM NaCl, 0.01% Tween 80, 1mM EDTA, 50% Glycerol,pH 8.0.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution
Storage Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway. Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses. Tryptophan shortage inhibits T lymphocytes division and accumulation of tryptophan catabolites induces T-cell apoptosis and differentiation of regulatory T-cells. Acts as a suppressor of anti-tumor immunity. Limits the growth of intracellular pathogens by depriving tryptophan. Protects the fetus from maternal immune rejection (Ref. 3).
Subcellular Location Cytoplasm, cytosol.
Protein Families Indoleamine 2,3-dioxygenase family
Database References
Tissue Specificity Highly expressed in epididymis, duodemum, jejunum, ileum, colon and spleen. Highly expressed in epididymis, prostate, duodemum, jejunum, ileum, colon and spleen, not detected in the liver (at protein level). Expressed in tumors only upon exposure to IFN g

Gene Functions References

  1. Influenza infection of NIH-3T3 cells elevates the expression of indoleamine 2,3 dioxygenase (IDO). Inhibition against IDO followed by infection increases the level of viral RNA and reduces the upregulation of 3-hydroxyanthranilate 3,4-dioxygenase driven by virus. Induction of IDO appears to contribute to limiting replication of the WSN/33 strain of influenza A virus in murine NIH-3T3 cells. PMID: 28402179
  2. Study showed that the knockout of IDO prevented vascular smooth muscle cells apoptosis in AngII -treated Ldlr-/- mice fed with HFD, suggesting a detrimental role of IDO in abdominal aortic aneurysm formation. PMID: 29494675
  3. The KYNurenine pathway of IDO1-mediated Tryptophan metabolism plays a critical role in depressive symptoms associated with IFN-alpha therapy. PMID: 27436416
  4. IDO is a critical regulator of acute pulmonary inflammation . PMID: 28673995
  5. Data suggest that Indoleamine 2,3-dioxygenase 1 (IDO1) appears to be a potential hallmark of liver lesions, and its deficiency protects mice from CCl4-induced fibrosis mediated by Th17 cells down-regulation and tryptophan 2,3-dioxygenase (TDO) compensatory increase. PMID: 28465467
  6. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment PMID: 27705910
  7. Findings suggest non-redundant neurophysiological roles for indoleamine 2,3-dioxygenase 1, indoleamine 2,3-dioxygenase 2 and tryptophan 2,3-dioxygenase in modulating brain activities and metabolism. PMID: 27316339
  8. These results show IDO is upregulated with RSV infection and this upregulation likely participates with IFN-gamma in inhibition of virus replication and suppression of some host cell responses to infection. PMID: 28963880
  9. Lipopolysaccharide (LPS) stimulation increased the expression and activity of the immunoregulatory enzyme IDO1 in hepatic stellate cells (HSCs), and LPS/HSCs stimulated aryl hydrocarbon receptor (AhR) signaling in cocultured regulatory T cells. PMID: 27581538
  10. this study shows that the presence of IFN-alpha at antigen sensitization activates an IDO1/TGF-beta-dependent anti-inflammatory program that upon antigenic rechallenge prevents inflammation via plasmacytoid dendritic cells PMID: 27647832
  11. The deficiency of indoleamine 2,3-dioxygenase aggravates the carbon tetrachloride-induced liver fibrosis in mice. PMID: 27598994
  12. Across strains, networks depicted a predominance of genes under-expressed in microglia relative to macrophages that may be a precursor for the different response of both cell types to challenges. The detected transcriptome differences enhance the understanding of the role of IDO1 in the microglia transcriptome under unchallenged conditions. PMID: 27314674
  13. Data show that indoleamine 23-dioxygenase 1 (IDO-1) inhibitors 1-methyl-D-tryptophan was able to alleviate most of the behavioural changes resulting from unpredictable chronic mild stress (UCMS) exposure. PMID: 27828964
  14. IDO did not play a pivotal role in the suppression of allergic airway inflammation through adipose-derived stem cells, suggesting that it is not the major regulator responsible for suppressing allergic airway inflammation. PMID: 27812173
  15. Aortic Plasmacytoid dendritic cells expressed CCR9 and indoleamine 2,3-dioxygenase 1 (IDO-1), an enzyme involved in driving the generation of regulatory T cells (Tregs). PMID: 27166946
  16. Indoleamine-2,3-dioxygenase (IDO) production by Plasmacytoid dendritic cells (pDCs)is necessary to confer suppressive function to T-Cells, Regulatory (Tregs) in experimental autoimmune encephalomyelitis (EAE). PMID: 27470005
  17. our findings support the hypothesis elevated IDO activity in non-CNS due to virus infections causes pain hypersensitivity PMID: 27168185
  18. this study shows that IDO overexpression in dendritic cells attenuates acute allograft rejection PMID: 27107370
  19. This insight into IDO1's involvement in pro-tumorigenic inflammatory neovascularization may have important ramifications for IDO1 inhibitor development, not only in cancer where clinical trials are currently ongoing, but in other disease indications associated with neovascularization as well. PMID: 27889479
  20. Inhibition of IDO activity ameliorated Japanese encephalitis via enhancement of antiviral IFN-I/II innate and adaptive T-cell responses and increased central nervous system infiltration of peripheral leukocytes. PMID: 27090635
  21. Results suggest that IDO expression is implicated in immunosuppression and tumor progression in glioma cells; combining IDO inhibition with standard TMZ treatment could be an encouraging therapeutic strategy for patients with malignant glioma PMID: 26636389
  22. Data show that the expression of indoleamine 2, 3-dioxygenase 1 (IDO) was decreased after tumor cells were infected with Salmonella. PMID: 26517244
  23. Severity of sodium dodecyl sulfate-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networks. PMID: 26610689
  24. Data implicate indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism as a pathogenic factor for cognitive dysfunction in inflammation-induced depressive disorders and a potential novel target for the treatment of these disorders. PMID: 26130057
  25. IDO1 deficiency does not affect inflammation in Systemic Juvenile Idiopathic Arthritis, Secondary Hemophagocytic Lymphohistiocytosis and a T cell-triggered cytokine release model. PMID: 26914138
  26. Increased expression of IDO in liver cell adenomas compared to the surrounding normal tissue may create a microenvironment that promotes the progression of HCC by suppressing the proliferation of cytotoxic T lymphocytes and enhancing Tregs. PMID: 26727596
  27. Chimeric vaccine stimulation of human dendritic cell IDO1 occurs via the non-canonical NF-kappaB pathway. PMID: 26881431
  28. Absence of Ido1 protects against atherosclerosis through increase of Il10. PMID: 26235422
  29. Indoleamine 2,3-Dioxygenase Is Involved in the Inflammation Response of Corneal Epithelial Cells to Aspergillus fumigatus Infections PMID: 26361229
  30. the role of IFN-lambda in IDO regulation was investigated after influenza infection of respiratory epithelial cells. PMID: 25756191
  31. TNF-alpha mediates stress-induced depression by upregulating indoleamine 2,3-dioxygenase in a mouse model of unpredictable chronic mild stress. PMID: 26083579
  32. Experimental hemophilic mouse models with or without functional IDO1 revealed that tryptophan metabolites, which result from IDO1 activity, prevent generation of anti-FVIII antibodies. PMID: 26426076
  33. Data indicate indoleamine 23-dioxygenase 1 IDO1 induction in B cells as a negative regulatory mechanism of the T Cell-independent antigens (TI) humoral immune response. PMID: 26216892
  34. IFN-gamma coordinately induces IDO1 and a tryptophan-selective transporter in human colonic epithelial cells and mouse dendritic cells with a positive feedback mechanism via kynurenine-AhR signaling. PMID: 25450809
  35. The data showed that there is not significant effect of IDO1 or TDO2 on mortality in pneumococcal meningitis. PMID: 24844751
  36. dendritic cell-based immune response mediated by interferon-gamma-induced IDO expression via GSK-3beta activity not only regulates CD8(+) T-cell proliferation and cytotoxic T lymphocyte activity but also modulates OVA-pulsed DC vaccination against EG7 thymoma PMID: 25814664
  37. Data suggest that transferred TGF-beta-induced regulatory T cells (iTregs) could induce tolerogenic splenic dendritic cells and these cells could effectively dampen collagen-induced arthritis in an indoleamine 2,3-dioxygenase (IDO)-dependent manner. PMID: 25405209
  38. 20 weeks of Western diet altered LPS-induced depressive-like behavior compared to LPS-treated lean mice and exacerbated hippocampal and hypothalamic proinflammatory cytokine expression and brain IDO activation. PMID: 24681251
  39. B7-2 costimulation and intracellular indoleamine 2,3-dioxygenase expression is reduced in umbilical cord blood as compared to adult peripheral blood. PMID: 24930629
  40. These data indicate that activation of brain IDO1 is sufficient to induce depression-like behaviors of mice in response to central LPS. PMID: 23866724
  41. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. PMID: 24402311
  42. Inhibitors were used to clarify the role of IDO in graft-vs-tumor reactions after allogeneic stem cell transplantation plus donor leukocyte infusion. IDO1 expression in tumor tissues and TDLN, but not spleen, was increased in the mice receiving DLI. PMID: 24971697
  43. The role of IDO during initial host response to influenza infection was studied by using a specific inhibitor. IDO inhibition enhanced lung proinflammatory cytokine gene and protein expression at 24 and 48 h post influenza virus infection. PMID: 24799604
  44. engagement of CD80/86 by CTLA-4 induced activation of the enzyme indoleamine 2,3-dioxygenase (IDO) in osteoclast precursors, which degraded tryptophan and promoted apoptosis PMID: 24807557
  45. The study indicates that IDO1 is spatiotemporally expressed in activated microglia during acute viral encephalitis by encephalomyocarditis virus. PMID: 24530381
  46. Systemic primary and recall T-cell CD8 responses to viral antigens are controlled by IDO. PMID: 24587363
  47. tumor-derived IDO promotes the peritoneal dissemination of ovarian cancer through creating an immunotolerogenic environment within the peritoneal cavity PMID: 24826982
  48. Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. PMID: 24580128
  49. Data indicate that the frequency and absolute number of Treg cells increased in indoleamine 2,3-dioxygenase (IDO) expressing fibroblast environment PMID: 23891282
  50. we address this issue with the development of IDO1 monoclonal antibody 4B7 which specifically recognizes the murine enzyme in tissue sections, offering a reliable tool for immunohistology in preclinical disease models. PMID: 24123235

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed